Phase 2 is where clinical development starts facing harder questions.
Does the therapy work in the right patient population? Is the selected dose justified? Are the endpoints strong enough to support the next decision? Is the study structure clear enough for sites, regulators and internal teams to execute without avoidable confusion?
This KITSA guide breaks down how sponsors, CROs and medical writers can structure a Phase 2 clinical trial protocol around regulatory expectations, endpoint logic, eligibility criteria, safety monitoring, statistical planning and ICH M11 alignment.
The larger point is simple. A Phase 2 protocol is not just a document. It is a decision framework that shapes whether a program can move into Phase 3 with confidence.